Xenova (XNVA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xenova (XNVA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	5/15/2005 3:52:47 PM
	of 173

>>MarketWatch Market Pulse: Cytos: Nicotine addiction vaccine has proof of efficacy Saturday May 14, 4:54 pm ET By Carla Mozee SAN FRANCISCO (MarketWatch) -- Cytos Biotechnology AG said Saturday that its vaccine candidate to treat nicotine addiction has achieved proof of efficacy in a Phase II clinical trial. Cytos said two-thirds of the study's 341 participants received the CYT002-NicQb vaccine, with one-third receiving placebo. The Swiss company said that efficacy was determined by continuous abstinence from smoking between weeks 8 and 24 after the start of the treatment.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next